Dr Stephanie Davies leads Valitacell’s team in AutoCRAT
AutoCRAT partners, Valitacell, (www.valitacell.com) a Dublin-headquartered biotechnology SME, has been selected by as one of eleven high potential global start-ups to join the prestigious health tech accelerator programme Startup Creasphere. Since 2014, award-winning Valitacell produces innovative products and technologies for the biopharmaceutical industry. Valitacell’s products enable biopharmaceutical companies to bring drugs to the market quicker, cheaper and with greater regulatory confidence.
Established in 2018, by Roche and Plug and Play, Startup Creasphere is a Digital Health Accelerator innovation programme that matches global pharmaceutical partners including Roche, Sanofi and Lonza with the world’s most innovative and disruptive health tech start-ups. The global healthcare giant Lonza has chosen to collaborate with Valitacell as their chosen high potential start-up for the 3-month programme.
Commenting on the partnership, Dr Stephanie Davies, Head of Cell Therapy at Valitacell remarked:
“Valitacell is delighted to have been chosen by Lonza for this 3-month accelerator programme and we look forward to working with Lonza to transform healthcare together.”
About Lonza: Founded in Switzerland in 1897, Lonza is a leading global provider of integrated healthcare solutions employing 15,500 employees across 35 countries and generating over €5.5bn annually.
Read Valitacell’s press release here.
